AE Wealth Management LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 373.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,381 shares of the medical research company’s stock after acquiring an additional 12,924 shares during the quarter. AE Wealth Management LLC’s holdings in IQVIA were worth $2,967,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in IQV. Bishop Rock Capital L.P. raised its holdings in shares of IQVIA by 14,549.4% in the 2nd quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock worth $18,667,000 after purchasing an additional 4,022,902 shares during the period. CIBC Private Wealth Group LLC bought a new position in IQVIA during the 2nd quarter worth approximately $182,868,000. State Street Corp lifted its holdings in IQVIA by 4.6% during the 1st quarter. State Street Corp now owns 8,306,345 shares of the medical research company’s stock worth $1,920,510,000 after buying an additional 362,541 shares during the last quarter. Artemis Investment Management LLP lifted its holdings in shares of IQVIA by 77.6% in the 2nd quarter. Artemis Investment Management LLP now owns 552,506 shares of the medical research company’s stock worth $120,138,000 after purchasing an additional 241,433 shares during the last quarter. Finally, Amundi lifted its holdings in shares of IQVIA by 11.3% in the 2nd quarter. Amundi now owns 2,078,718 shares of the medical research company’s stock worth $440,687,000 after purchasing an additional 211,026 shares during the last quarter. 86.20% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Price Performance
IQV stock opened at $205.36 on Friday. The stock has a 50-day moving average price of $210.68 and a two-hundred day moving average price of $210.89. The stock has a market cap of $38.14 billion, a PE ratio of 33.45, a price-to-earnings-growth ratio of 2.14 and a beta of 1.37. The company has a current ratio of 0.90, a quick ratio of 0.90 and a debt-to-equity ratio of 2.29. IQVIA Holdings Inc. has a 1 year low of $165.75 and a 1 year high of $263.95.
Analyst Ratings Changes
Several analysts have weighed in on the company. Cowen assumed coverage on IQVIA in a research note on Tuesday, December 6th. They set an “outperform” rating and a $251.00 target price on the stock. Morgan Stanley lowered their price target on IQVIA from $260.00 to $240.00 and set an “overweight” rating on the stock in a research report on Thursday, October 27th. Guggenheim lifted their target price on IQVIA to $249.00 in a report on Thursday, October 27th. Barclays lifted their price target on IQVIA from $215.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, October 27th. Finally, Robert W. Baird lifted their price target on IQVIA to $266.00 in a report on Thursday, October 27th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $257.13.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don’t Buy It Just Yet
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.